These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 12460324

  • 1. Effect of withdrawal of somatostatin plus growth hormone (GH)-releasing hormone as a stimulus of GH secretion in Cushing's syndrome.
    Leal-Cerro A, Soto A, Martínez MA, Alvarez P, Isidro L, Casanueva FF, Dieguez C, Cordido F.
    Clin Endocrinol (Oxf); 2002 Dec; 57(6):745-9. PubMed ID: 12460324
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Growth hormone (GH) rebound rise following somatostatin infusion withdrawal: studies in dogs with the use of GH-releasing hormone and a GH-releasing peptide.
    Rigamonti AE, Cavallera G, Bonomo S, Deghenghi R, Locatelli V, Cella SG, Müller EE.
    Eur J Endocrinol; 2001 Nov; 145(5):635-44. PubMed ID: 11720883
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Somatostatin infusion withdrawal: studies in the acute and recovery phase of anorexia nervosa, and in obesity.
    Pincelli AI, Rigamonti AE, Scacchi M, Cella SG, Cappa M, Cavagnini F, Müller EE.
    Eur J Endocrinol; 2003 Feb; 148(2):237-43. PubMed ID: 12590644
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Interaction of the growth hormone releasing peptide hexarelin with somatostatin.
    Massoud AF, Hindmarsh PC, Brook CG.
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):537-47. PubMed ID: 9425393
    [Abstract] [Full Text] [Related]

  • 8. Growth hormone releasing hormone priming increases growth hormone secretion in patients with Cushing's syndrome.
    Leal-Cerro A, Pumar A, Villamil F, Astorga R, Dieguez C, Casanueva FF.
    Clin Endocrinol (Oxf); 1993 Apr; 38(4):399-403. PubMed ID: 8319372
    [Abstract] [Full Text] [Related]

  • 9. Effect of galanin on the growth hormone (GH) response to GH-releasing hormone in patients with Cushing's disease.
    Giustina A, Bossoni S, Bussi AR, Pozzi A, Wehrenberg WB.
    Endocr Res; 1993 Mar; 19(1):47-56. PubMed ID: 7681769
    [Abstract] [Full Text] [Related]

  • 10. Marked GH secretion after ghrelin alone or combined with GH-releasing hormone (GHRH) in obese patients.
    Alvarez-Castro P, Isidro ML, Garcia-Buela J, Leal-Cerro A, Broglio F, Tassone F, Ghigo E, Dieguez C, Casanueva FF, Cordido F.
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):250-5. PubMed ID: 15272922
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pyridostigmine enhances even if it does not normalize the growth hormone responses to growth hormone-releasing hormone in patients with Cushing's disease.
    Giustina A, Bossoni S, Bodini C, Ferrari C, Pizzocolo G, Scalvini T, Schettino M, Wehrenberg WB.
    Horm Res; 1991 Aug; 35(3-4):99-103. PubMed ID: 1806475
    [Abstract] [Full Text] [Related]

  • 13. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
    Procopio M, Invitti C, Maccario M, Grottoli S, Cavagnini F, Camanni F, Ghigo E.
    Int J Obes Relat Metab Disord; 1995 Feb; 19(2):108-12. PubMed ID: 7735336
    [Abstract] [Full Text] [Related]

  • 14. Abuse of recombinant human growth hormone: studies in two different dog models.
    Rigamonti AE, Scanniffio D, Bonomo SM, Cella SG, Sartorio A, Müller EE.
    Neuroendocrinology; 2004 Feb; 79(5):237-46. PubMed ID: 15218318
    [Abstract] [Full Text] [Related]

  • 15. Acute pharmacological reduction of plasma free fatty acids enhances the growth hormone (GH)-releasing hormone-mediated GH secretion in patients with Cushing's syndrome.
    Leal-Cerro A, Jimenez LM, Astorga R, Fernandez-Lopez I, Dieguez C, Casanueva FF.
    J Clin Endocrinol Metab; 1997 Sep; 82(9):3165-8. PubMed ID: 9284763
    [Abstract] [Full Text] [Related]

  • 16. Somatostatin withdrawal as generator of pulsatile GH release in the dog: a possible tool to evaluate the endogenous GHRH tone?
    Cella SG, Luceri M, Cattaneo L, Torsello A, Müller EE.
    Neuroendocrinology; 1996 Jun; 63(6):481-8. PubMed ID: 8793889
    [Abstract] [Full Text] [Related]

  • 17. Contribution of growth hormone-releasing hormone and somatostatin to decreased growth hormone secretion in elderly men.
    Soule SG, Macfarlane P, Levitt NS, Millar RP.
    S Afr Med J; 2001 Mar; 91(3):254-60. PubMed ID: 11291426
    [Abstract] [Full Text] [Related]

  • 18. Effect of enhancement of endogenous cholinergic tone with pyridostigmine on growth hormone (GH) responses to GH-releasing hormone in patients with Cushing's syndrome.
    Leal-Cerro A, Pereira JL, Garcia-Luna PP, Astorga R, Cordido F, Casanueva FF, Dieguez C.
    Clin Endocrinol (Oxf); 1990 Aug; 33(2):291-5. PubMed ID: 2225484
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The sequential administration of growth hormone-releasing hormone followed 120 minutes later by hexarelin, as an effective test to assess the pituitary GH reserve in man.
    Micic D, Popovic V, Kendereski A, Peino R, Dieguez C, Casanueva FF.
    Clin Endocrinol (Oxf); 1996 Nov; 45(5):543-51. PubMed ID: 8977750
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.